REPORT ID 3785

EMEA (Europe, Middle East and Africa) Fragile X Syndrome Market Report 2017

Publish Date
14-Dec-17
Pages
112
Format
Electronic (PDF)

In this report, the EMEA Fragile X Syndrome market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Fragile X Syndrome for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Fragile X Syndrome market competition by top manufacturers/players, with Fragile X Syndrome sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Aelis Farma SAS
    Alcobra Ltd
    AMO Pharma Limited
    Confluence Pharmaceuticals LLC
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd.
    Marinus Pharmaceuticals, Inc.
    MI.TO. Technology S.r.L.
    Neuren Pharmaceuticals Limited
    Ovid Therapeutics Inc.
    Sage Therapeutics, Inc.
    Zynerba Pharmaceuticals, Inc.

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    ACT-01
    AMO-01
    ANAVEX-273
    AUT-00206
    Bryostatin-1
    Cannabidiol
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Clinic
    Hopital
    Research Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Fragile X Syndrome Market Report 2017
1 Fragile X Syndrome Overview
    1.1 Product Overview and Scope of Fragile X Syndrome
    1.2 Classification of Fragile X Syndrome
        1.2.1 EMEA Fragile X Syndrome Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Fragile X Syndrome Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 ACT-01
        1.2.4 AMO-01
        1.2.5 ANAVEX-273
        1.2.6 AUT-00206
        1.2.7 Bryostatin-1
        1.2.8 Cannabidiol
        1.2.9 Others
    1.3 EMEA Fragile X Syndrome Market by Application/End Users
        1.3.1 EMEA Fragile X Syndrome Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Clinic
        1.3.3 Hopital
        1.3.4 Research Center
    1.4 EMEA Fragile X Syndrome Market by Region
        1.4.1 EMEA Fragile X Syndrome Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Fragile X Syndrome (2012-2022)
        1.5.1 EMEA Fragile X Syndrome Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Fragile X Syndrome Revenue and Growth Rate (2012-2022)

2 EMEA Fragile X Syndrome Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Fragile X Syndrome Market Competition by Players/Manufacturers
        2.1.1 EMEA Fragile X Syndrome Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Fragile X Syndrome Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Fragile X Syndrome Sale Price by Players (2012-2017)
    2.2 EMEA Fragile X Syndrome (Volume and Value) by Type/Product Category
        2.2.1 EMEA Fragile X Syndrome Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Fragile X Syndrome Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Fragile X Syndrome Sale Price by Type (2012-2017)
    2.3 EMEA Fragile X Syndrome (Volume) by Application
    2.4 EMEA Fragile X Syndrome (Volume and Value) by Region
        2.4.1 EMEA Fragile X Syndrome Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Fragile X Syndrome Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Fragile X Syndrome Sales Price by Region (2012-2017)

3 Europe Fragile X Syndrome (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Fragile X Syndrome Sales and Value (2012-2017)
        3.1.1 Europe Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Fragile X Syndrome Revenue and Growth Rate (2012-2017)
    3.2 Europe Fragile X Syndrome Sales and Market Share by Type
    3.3 Europe Fragile X Syndrome Sales and Market Share by Application
    3.4 Europe Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Fragile X Syndrome Sales Volume by Countries (2012-2017)
        3.4.2 Europe Fragile X Syndrome Revenue by Countries (2012-2017)
        3.4.3 Germany Fragile X Syndrome Sales and Growth Rate (2012-2017)
        3.4.4 France Fragile X Syndrome Sales and Growth Rate (2012-2017)
        3.4.5 UK Fragile X Syndrome Sales and Growth Rate (2012-2017)
        3.4.6 Russia Fragile X Syndrome Sales and Growth Rate (2012-2017)
        3.4.7 Italy Fragile X Syndrome Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Fragile X Syndrome Sales and Growth Rate (2012-2017)

4 Middle East Fragile X Syndrome (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Fragile X Syndrome Sales and Value (2012-2017)
        4.1.1 Middle East Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Fragile X Syndrome Revenue and Growth Rate (2012-2017)
    4.2 Middle East Fragile X Syndrome Sales and Market Share by Type
    4.3 Middle East Fragile X Syndrome Sales and Market Share by Application
    4.4 Middle East Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Fragile X Syndrome Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Fragile X Syndrome Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Fragile X Syndrome Sales and Growth Rate (2012-2017)
        4.4.4 Israel Fragile X Syndrome Sales and Growth Rate (2012-2017)
        4.4.5 UAE Fragile X Syndrome Sales and Growth Rate (2012-2017)
        4.4.6 Iran Fragile X Syndrome Sales and Growth Rate (2012-2017)

5 Africa Fragile X Syndrome (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Fragile X Syndrome Sales and Value (2012-2017)
        5.1.1 Africa Fragile X Syndrome Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Fragile X Syndrome Revenue and Growth Rate (2012-2017)
    5.2 Africa Fragile X Syndrome Sales and Market Share by Type
    5.3 Africa Fragile X Syndrome Sales and Market Share by Application
    5.4 Africa Fragile X Syndrome Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Fragile X Syndrome Sales Volume by Countries (2012-2017)
        5.4.2 Africa Fragile X Syndrome Revenue by Countries (2012-2017)
        5.4.3 South Africa Fragile X Syndrome Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Fragile X Syndrome Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Fragile X Syndrome Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Fragile X Syndrome Sales and Growth Rate (2012-2017)

6 EMEA Fragile X Syndrome Manufacturers/Players Profiles and Sales Data
    6.1 Aelis Farma SAS
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Fragile X Syndrome Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Aelis Farma SAS Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Alcobra Ltd
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Fragile X Syndrome Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Alcobra Ltd Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 AMO Pharma Limited
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Fragile X Syndrome Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 AMO Pharma Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Confluence Pharmaceuticals LLC
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Fragile X Syndrome Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Confluence Pharmaceuticals LLC Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Eli Lilly and Company
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Fragile X Syndrome Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Eli Lilly and Company Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 F. Hoffmann-La Roche Ltd.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Fragile X Syndrome Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Marinus Pharmaceuticals, Inc.
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Fragile X Syndrome Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 MI.TO. Technology S.r.L.
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Fragile X Syndrome Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 MI.TO. Technology S.r.L. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Neuren Pharmaceuticals Limited
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Fragile X Syndrome Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Neuren Pharmaceuticals Limited Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Ovid Therapeutics Inc.
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Fragile X Syndrome Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Ovid Therapeutics Inc. Fragile X Syndrome Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Sage Therapeutics, Inc.
    6.12 Zynerba Pharmaceuticals, Inc.

7 Fragile X Syndrome Manufacturing Cost Analysis
    7.1 Fragile X Syndrome Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Fragile X Syndrome

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Fragile X Syndrome Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Fragile X Syndrome Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Fragile X Syndrome Market Forecast (2017-2022)
    11.1 EMEA Fragile X Syndrome Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Fragile X Syndrome Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Fragile X Syndrome Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Fragile X Syndrome Price and Trend Forecast (2017-2022)
    11.2 EMEA Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Fragile X Syndrome Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Fragile X Syndrome Sales Forecast by Type (2017-2022)
    11.7 EMEA Fragile X Syndrome Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer